These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 571017)

  • 1. Dopaminergic antagonists: effects of 1,2,3,4-tetrahydroisoquinoline and its N-methyl and N-propyl homologs on apomorphine- and L-dopa-induced behavioral effects in rodents.
    Ginos JZ; Doroski D
    J Pharmacol Exp Ther; 1979 Apr; 209(1):79-86. PubMed ID: 571017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
    Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
    J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
    Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH
    J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N,N-dialkylated dopamines.
    Ginos JZ; Cotzias GC; Tolosa E; Tang LC; LoMonte A
    J Med Chem; 1975 Dec; 18(12):1194-1200. PubMed ID: 1238569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of some antidepressant drugs on apomorphine concentration in the central nervous system of rats and apomorphine-induced stereotypy.
    Rurak A; Melzacka M
    Pol J Pharmacol Pharm; 1985; 37(4):509-15. PubMed ID: 3866221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice.
    Thornburg JE; Moore KE
    J Pharmacol Exp Ther; 1975 Jan; 192(1):42-9. PubMed ID: 1168250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antagonism between L-DOPA and apomorphine in their effects on rat behavior].
    Allikmets LKh; Zharkovskiĭ Am; Vasar EE
    Biull Eksp Biol Med; 1977 Jul; 84(7):51-3. PubMed ID: 560890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine hypothermia: interaction with serotonergic agents.
    Kulkarni SK
    Pol J Pharmacol Pharm; 1980; 32(1):15-20. PubMed ID: 7192860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 12-chloroscoulerine enantiomers on animal behavior to dopamine receptors.
    Chen LJ; Zhou QT; Dong ZJ; Yu LP; Jin GZ
    Zhongguo Yao Li Xue Bao; 1999 Oct; 20(10):884-8. PubMed ID: 11270985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A; Havemann-Reinecke U
    J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some central effects of opioid antagonists. Part I.
    Skorupska M; Langwiński R
    Pol J Pharmacol Pharm; 1989; 41(5):401-11. PubMed ID: 2577060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
    Cole DG; Growdon JH; DiFiglia M
    Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.